Mount Sinai Researchers Find Link Between Exposure to World Trade Center Dust and Prostate Cancer
World Trade Center (WTC) responders with prostate cancer showed signs that exposure to dust from the World Trade Center site had activated chronic inflammation in their prostates, which may have contributed to their cancer, according to a study by Mount Sinai researchers in Molecular Cancer Research in June.
Inflammation has long been considered an important factor in prostate cancer progression. Researchers looked at the inflammatory and immune systems of World Trade Center responders to help prevent new prostate cancer cases in that group and to understand how other large-scale environmental exposures to multiple carcinogens may develop into cancer.
This is the first study of people who were exposed to the WTC dust and who subsequently developed prostate cancer. This research and further study of the expression of genes and pathways in other patients whose environmental exposures caused inflammation could lead to clinical trials that offer anti-inflammatory or immune-targeted therapies in similar cases.
“World Trade Center responders show an overall increase in cancer incidence, and specifically of certain cancer types such as prostate cancer,” said Emanuela Taioli, MD, PhD, Director of the Institute for Translational Epidemiology at the Icahn School of Medicine at Mount Sinai and Associate Director for Population Science at The Tisch Cancer Institute. “It is important to address the reasons why this is happening in order to prevent new cases in this aging cohort. Our findings represent the first link between exposure to World Trade Center dust and prostate cancer.”
This work pairs data from first responders and from a study of rats exposed to actual dust from Ground Zero. The dust samples, which contain metals and organic compounds such as polycyclic aromatic hydrocarbons and polychlorinated biphenyl, are unique because they are the only existing samples taken on September 11, 2001. All other dust samples were collected after a significant storm on September 14, 2001.
Both the human and rat prostate cancer tissues show an increase in cells that indicate inflammation, specifically immune cells called T helper cells. Studies of the rat tissue and prostate cancer tissue samples taken from responders indicated to the Mount Sinai researchers that chronic inflammation started occurring in the prostate after exposure to the World Trade Center dust, and that inflammation may have contributed to prostate cancer.
“Several years ago, I saw a first responder in his 40s who began having symptoms of prostatitis, a painful condition that involves inflammation of the prostate, soon after exposure to the World Trade Center dust,” said William Oh, MD, Chief of the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai and Deputy Director at The Tisch Cancer Institute. “He ultimately developed a high-grade prostate cancer several years later. It suggested to me that there might be a link between his exposure and cancer, but I knew that I would need to examine it systematically.”
This study was sponsored by grants from the U.S. Centers for Disease Control and Prevention, the National Institute for Occupational Safety and Health, the National Institutes of Health, and the National Institute of Environmental Health Sciences.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.